Real-world experience of tralokinumab for atopic dermatitis: A 16-week multicenter retrospective study

Tralokinumab is a novel IgG4 monoclonal antibody against interleukin-13 recently approved for moderate-to-severe atopic dermaitits (AD) in adults and adolescents. While its efficacy and safety have been demonstrated in clinical trials, real-world data remains limited. Herein, we provide evidence regarding tralokinumab use in routine clinical practice.